Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan

Rhea-AI Filing Summary

Stoke Therapeutics general counsel Jonathan Allan sold 9,293 shares of common stock in open-market transactions. The sales occurred on March 20, 2026 at weighted average prices of $33.64 and $34.41 per share under a pre-arranged Rule 10b5-1 trading plan. He continues to hold 19,543 shares directly after these trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		S(1)		8,692	D	$33.6354(2)	20,144	D
Common Stock	03/20/2026		S(1)		601	D	$34.4079(3)	19,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive.

	/s/ Jonathan Allan	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Stoke Therapeutics (STOK) report for Jonathan Allan?

Stoke Therapeutics reported that general counsel Jonathan Allan sold 9,293 shares of common stock. The sales were executed in two open-market transactions, and he directly held 19,543 shares of Stoke Therapeutics stock after the reported trades.

At what prices did Jonathan Allan sell Stoke Therapeutics (STOK) shares?

Jonathan Allan sold Stoke Therapeutics shares at weighted average prices of $33.64 and $34.41 per share. The Form 4 notes that each weighted price reflects multiple trades within price ranges disclosed in the filing’s footnotes for those open-market transactions.

When did the recent Stoke Therapeutics (STOK) insider sales by Jonathan Allan occur?

The reported Stoke Therapeutics insider sales by Jonathan Allan took place on March 20, 2026. Both transactions involved common stock and were categorized as open-market sales, as reflected by transaction code S in the Form 4 insider trading report.

How many Stoke Therapeutics (STOK) shares does Jonathan Allan own after the Form 4 transactions?

After selling 9,293 shares, Jonathan Allan directly owns 19,543 shares of Stoke Therapeutics common stock. This post-transaction holding figure is reported in the Form 4 and reflects his remaining direct equity position following the March 20, 2026 sales.

Were Jonathan Allan’s Stoke Therapeutics (STOK) share sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions.

What does transaction code S mean in the Stoke Therapeutics (STOK) Form 4 for Jonathan Allan?

Transaction code S in the Stoke Therapeutics Form 4 indicates open-market or private sale of common stock. For Jonathan Allan, both reported trades on March 20, 2026 are coded S, confirming they were dispositions of shares rather than option exercises or grants.